Clinical Trials
11 trialsNCT07499362 2026-05-28
Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER)
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 2 Recruiting
NCT05804045 2026-05-04
Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)
Abbisko Therapeutics Co, Ltd
Phase 3 Active not recruiting
NCT05059262 2026-03-20
MOTION
Deciphera Pharmaceuticals, LLC
Phase 3 Active not recruiting
NCT04192344 2026-03-19
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor
Abbisko Therapeutics Co, Ltd
Phase 1 Recruiting
NCT04703322 2026-03-04
A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in Japan
Daiichi Sankyo
Phase 2 Active not recruiting
NCT01207492 2026-02-20
Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor
Dana-Farber Cancer Institute
Phase 2 Completed
NCT07315841 2026-01-05
ICG-TGCT
Shanghai Jiao Tong University Affiliated Sixth People's Hospital
Phase 4 Recruiting
NCT03069469 2025-12-18
Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor
Deciphera Pharmaceuticals, LLC
Phase 1/2 Active not recruiting
NCT07075471 2025-11-05
Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib
Deciphera Pharmaceuticals, LLC
Recruiting
NCT04635111 2025-10-06
A Long-term Study Evaluating Hepatotoxicity Associated With TURALIOâ„¢ (Pexidartinib) Treatment
Daiichi Sankyo
Recruiting
NCT04488822 2025-09-09
PLX3397
Daiichi Sankyo
Phase 3 Active not recruiting